 Susan Apkon
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophy, Duchenne | 22 | 2025 | 89 | 5.310 |
Why?
| | Osteoporosis | 5 | 2014 | 233 | 1.320 |
Why?
| | Spinal Muscular Atrophies of Childhood | 2 | 2018 | 14 | 1.050 |
Why?
| | Orthopedic Procedures | 2 | 2019 | 206 | 1.030 |
Why?
| | Bone Density | 6 | 2014 | 474 | 1.000 |
Why?
| | Exercise Therapy | 4 | 2019 | 412 | 0.900 |
Why?
| | Myotonic Dystrophy | 1 | 2022 | 8 | 0.760 |
Why?
| | Disabled Children | 4 | 2021 | 66 | 0.640 |
Why?
| | Morpholinos | 1 | 2019 | 31 | 0.630 |
Why?
| | Neuromuscular Diseases | 1 | 2020 | 105 | 0.590 |
Why?
| | Inpatients | 4 | 2016 | 464 | 0.580 |
Why?
| | Disease Management | 3 | 2020 | 583 | 0.580 |
Why?
| | Musculoskeletal Diseases | 1 | 2018 | 69 | 0.570 |
Why?
| | Pandemics | 3 | 2020 | 1473 | 0.550 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 32 | 0.540 |
Why?
| | Physical Therapy Modalities | 2 | 2017 | 292 | 0.530 |
Why?
| | Alaska Natives | 2 | 2016 | 137 | 0.530 |
Why?
| | Rehabilitation | 1 | 2016 | 16 | 0.500 |
Why?
| | Child | 29 | 2022 | 20636 | 0.500 |
Why?
| | Walking | 2 | 2023 | 495 | 0.490 |
Why?
| | Myelitis | 1 | 2017 | 98 | 0.490 |
Why?
| | Occupational Therapy | 1 | 2017 | 85 | 0.490 |
Why?
| | Spinal Dysraphism | 2 | 2024 | 59 | 0.470 |
Why?
| | Muscle Spasticity | 2 | 2016 | 55 | 0.450 |
Why?
| | Recovery of Function | 6 | 2019 | 630 | 0.440 |
Why?
| | Primary Health Care | 3 | 2018 | 1639 | 0.430 |
Why?
| | Cerebral Palsy | 2 | 2016 | 93 | 0.410 |
Why?
| | Healthcare Disparities | 2 | 2016 | 579 | 0.410 |
Why?
| | Terminal Care | 1 | 2016 | 234 | 0.400 |
Why?
| | Lumbosacral Region | 1 | 2012 | 56 | 0.400 |
Why?
| | Parents | 1 | 2021 | 1303 | 0.390 |
Why?
| | Muscular Dystrophies | 2 | 2012 | 34 | 0.380 |
Why?
| | Neural Tube Defects | 1 | 2012 | 63 | 0.380 |
Why?
| | Fractures, Bone | 2 | 2015 | 393 | 0.380 |
Why?
| | Humans | 51 | 2025 | 128020 | 0.380 |
Why?
| | Femur | 1 | 2012 | 245 | 0.350 |
Why?
| | Pediatrics | 1 | 2018 | 1044 | 0.350 |
Why?
| | Anti-Dyskinesia Agents | 1 | 2010 | 6 | 0.340 |
Why?
| | Critical Illness | 1 | 2016 | 755 | 0.340 |
Why?
| | Neuromuscular Agents | 1 | 2010 | 30 | 0.330 |
Why?
| | Botulinum Toxins | 1 | 2010 | 38 | 0.330 |
Why?
| | Caregivers | 4 | 2024 | 810 | 0.320 |
Why?
| | Diphosphonates | 2 | 2015 | 56 | 0.320 |
Why?
| | Brain Injuries, Traumatic | 3 | 2021 | 337 | 0.320 |
Why?
| | Muscular Atrophy, Spinal | 2 | 2020 | 21 | 0.310 |
Why?
| | Decision Making | 1 | 2016 | 846 | 0.310 |
Why?
| | Delivery of Health Care | 2 | 2022 | 888 | 0.310 |
Why?
| | Oligonucleotides | 2 | 2020 | 138 | 0.290 |
Why?
| | Alendronate | 1 | 2008 | 15 | 0.290 |
Why?
| | Meningomyelocele | 1 | 2008 | 58 | 0.290 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 71 | 0.280 |
Why?
| | Down Syndrome | 1 | 2012 | 469 | 0.250 |
Why?
| | Rehabilitation Centers | 2 | 2016 | 37 | 0.240 |
Why?
| | Male | 26 | 2024 | 62758 | 0.230 |
Why?
| | Health Services Accessibility | 2 | 2024 | 895 | 0.220 |
Why?
| | Prednisone | 2 | 2021 | 230 | 0.220 |
Why?
| | Global Health | 2 | 2020 | 327 | 0.220 |
Why?
| | Angelman Syndrome | 1 | 2023 | 11 | 0.210 |
Why?
| | Injections, Spinal | 2 | 2020 | 106 | 0.200 |
Why?
| | Adolescent | 14 | 2024 | 20158 | 0.200 |
Why?
| | Child, Preschool | 12 | 2024 | 10378 | 0.200 |
Why?
| | Physical and Rehabilitation Medicine | 1 | 2022 | 30 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2018 | 1482 | 0.190 |
Why?
| | Emergency Medical Services | 2 | 2018 | 518 | 0.190 |
Why?
| | Codon, Nonsense | 1 | 2021 | 39 | 0.190 |
Why?
| | Cone-Beam Computed Tomography | 2 | 2020 | 30 | 0.190 |
Why?
| | Social Determinants of Health | 1 | 2024 | 220 | 0.180 |
Why?
| | Comorbidity | 3 | 2020 | 1537 | 0.180 |
Why?
| | Neoplasms | 1 | 2015 | 2460 | 0.180 |
Why?
| | Lumbar Vertebrae | 2 | 2016 | 230 | 0.180 |
Why?
| | Florida | 1 | 2021 | 92 | 0.180 |
Why?
| | Medicine | 1 | 2022 | 117 | 0.180 |
Why?
| | Retrospective Studies | 11 | 2022 | 14404 | 0.170 |
Why?
| | Absorptiometry, Photon | 2 | 2014 | 248 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2025 | 572 | 0.170 |
Why?
| | Indians, North American | 2 | 2016 | 599 | 0.170 |
Why?
| | Education, Special | 1 | 2020 | 24 | 0.170 |
Why?
| | Female | 20 | 2024 | 68017 | 0.170 |
Why?
| | Schools | 2 | 2021 | 436 | 0.160 |
Why?
| | Intubation, Intratracheal | 1 | 2022 | 238 | 0.160 |
Why?
| | Movement | 1 | 2021 | 269 | 0.160 |
Why?
| | Orthotic Devices | 1 | 2018 | 23 | 0.150 |
Why?
| | Endocrine System | 1 | 2018 | 20 | 0.150 |
Why?
| | Spinal Cord | 1 | 2020 | 353 | 0.140 |
Why?
| | Neuromuscular Junction | 1 | 2018 | 57 | 0.140 |
Why?
| | Behavioral Symptoms | 1 | 2018 | 41 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2703 | 0.140 |
Why?
| | Postoperative Care | 1 | 2019 | 235 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.140 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 327 | 0.140 |
Why?
| | Neurological Rehabilitation | 1 | 2017 | 5 | 0.140 |
Why?
| | Radiography, Interventional | 1 | 2017 | 104 | 0.140 |
Why?
| | Rhizotomy | 1 | 2016 | 4 | 0.130 |
Why?
| | Laminectomy | 1 | 2016 | 28 | 0.130 |
Why?
| | Respiratory System | 1 | 2018 | 152 | 0.130 |
Why?
| | Cardiovascular System | 1 | 2018 | 136 | 0.130 |
Why?
| | Quality of Life | 2 | 2018 | 2672 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3009 | 0.120 |
Why?
| | Gastrointestinal Tract | 1 | 2018 | 182 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 275 | 0.120 |
Why?
| | Infant | 6 | 2024 | 8912 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 337 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4853 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2017 | 219 | 0.120 |
Why?
| | Electric Impedance | 1 | 2015 | 101 | 0.120 |
Why?
| | Bone and Bones | 1 | 2018 | 298 | 0.120 |
Why?
| | Range of Motion, Articular | 1 | 2017 | 361 | 0.120 |
Why?
| | Students | 1 | 2020 | 570 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2024 | 5688 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 302 | 0.110 |
Why?
| | Wheelchairs | 2 | 2015 | 14 | 0.110 |
Why?
| | Length of Stay | 2 | 2016 | 1114 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2016 | 254 | 0.110 |
Why?
| | Siblings | 1 | 2014 | 215 | 0.110 |
Why?
| | Mental Health Services | 1 | 2018 | 400 | 0.100 |
Why?
| | Patient Participation | 1 | 2017 | 409 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 500 | 0.100 |
Why?
| | Minority Groups | 1 | 2015 | 250 | 0.100 |
Why?
| | Internship and Residency | 1 | 2022 | 1043 | 0.100 |
Why?
| | Self Care | 1 | 2015 | 368 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1408 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 505 | 0.100 |
Why?
| | Muscle Strength | 1 | 2015 | 304 | 0.100 |
Why?
| | Standard of Care | 1 | 2012 | 72 | 0.090 |
Why?
| | Cohort Studies | 1 | 2022 | 5378 | 0.090 |
Why?
| | Risk Factors | 4 | 2015 | 9696 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2012 | 253 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5034 | 0.090 |
Why?
| | Radiography | 1 | 2012 | 794 | 0.090 |
Why?
| | Brain Injuries | 1 | 2015 | 463 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| | Vitamin D | 2 | 2015 | 380 | 0.080 |
Why?
| | Fractures, Spontaneous | 1 | 2008 | 11 | 0.080 |
Why?
| | Calcium, Dietary | 1 | 2008 | 56 | 0.070 |
Why?
| | Neurologic Examination | 1 | 2008 | 115 | 0.070 |
Why?
| | United States | 6 | 2024 | 13785 | 0.070 |
Why?
| | Mobility Limitation | 1 | 2008 | 58 | 0.070 |
Why?
| | Sex Factors | 1 | 2014 | 1942 | 0.070 |
Why?
| | Calcium | 2 | 2015 | 1182 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 2 | 2024 | 518 | 0.070 |
Why?
| | Disease Progression | 1 | 2014 | 2598 | 0.070 |
Why?
| | Hospitalization | 1 | 2016 | 2057 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 305 | 0.060 |
Why?
| | Torticollis | 1 | 2005 | 11 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1620 | 0.060 |
Why?
| | Adult | 7 | 2024 | 35177 | 0.060 |
Why?
| | Young Adult | 5 | 2024 | 12282 | 0.060 |
Why?
| | Botulinum Toxins, Type A | 1 | 2005 | 39 | 0.060 |
Why?
| | Palliative Care | 1 | 2011 | 714 | 0.060 |
Why?
| | Age Factors | 3 | 2015 | 3100 | 0.050 |
Why?
| | Risk Assessment | 3 | 2017 | 3223 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1272 | 0.050 |
Why?
| | Incidence | 3 | 2015 | 2614 | 0.050 |
Why?
| | Educational Status | 1 | 2024 | 470 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2024 | 164 | 0.050 |
Why?
| | Pregnenediones | 1 | 2021 | 20 | 0.050 |
Why?
| | Medicaid | 2 | 2017 | 433 | 0.050 |
Why?
| | Prednisolone | 1 | 2021 | 82 | 0.050 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 23 | 0.050 |
Why?
| | Video Recording | 1 | 2021 | 161 | 0.040 |
Why?
| | Telephone | 1 | 2021 | 165 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1211 | 0.040 |
Why?
| | Gait | 1 | 2023 | 277 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2023 | 759 | 0.040 |
Why?
| | Knee Joint | 1 | 2023 | 367 | 0.040 |
Why?
| | Fluoroscopy | 1 | 2020 | 156 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 997 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2646 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 170 | 0.040 |
Why?
| | Biomarkers | 1 | 2009 | 3874 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 756 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 433 | 0.040 |
Why?
| | Health Personnel | 1 | 2024 | 645 | 0.040 |
Why?
| | Nutrition Therapy | 1 | 2018 | 31 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2021 | 860 | 0.040 |
Why?
| | Internal Fixators | 1 | 2017 | 34 | 0.040 |
Why?
| | Washington | 1 | 2017 | 148 | 0.030 |
Why?
| | Appointments and Schedules | 1 | 2017 | 81 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1559 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1290 | 0.030 |
Why?
| | Iowa | 1 | 2015 | 24 | 0.030 |
Why?
| | Myography | 1 | 2015 | 4 | 0.030 |
Why?
| | Muscle Strength Dynamometer | 1 | 2015 | 22 | 0.030 |
Why?
| | Culturally Competent Care | 1 | 2016 | 57 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 78 | 0.030 |
Why?
| | Arizona | 1 | 2015 | 78 | 0.030 |
Why?
| | New York | 1 | 2015 | 124 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 133 | 0.030 |
Why?
| | Prospective Studies | 2 | 2021 | 7035 | 0.030 |
Why?
| | Prognosis | 2 | 2014 | 3766 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 500 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 816 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4369 | 0.030 |
Why?
| | Time Factors | 2 | 2015 | 6479 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 5353 | 0.020 |
Why?
| | Scoliosis | 1 | 2014 | 201 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2016 | 343 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1264 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2012 | 211 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2014 | 335 | 0.020 |
Why?
| | Health Status | 1 | 2015 | 747 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 57 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 78 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 490 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1896 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 10110 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 396 | 0.020 |
Why?
| | Cognition | 1 | 2015 | 1104 | 0.020 |
Why?
| | Injections, Intramuscular | 1 | 2005 | 115 | 0.020 |
Why?
| | Middle Aged | 2 | 2020 | 30813 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 755 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1943 | 0.010 |
Why?
|
|
Apkon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|